vs
礼蓝动物保健（ELAN）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
Roper Technologies的季度营收约是礼蓝动物保健的1.8倍（$2.1B vs $1.1B），Roper Technologies净利率更高（15.8% vs -24.1%，领先39.9%），礼蓝动物保健同比增速更快（12.2% vs 11.3%），Roper Technologies自由现金流更多（$507.0M vs $46.0M），过去两年Roper Technologies的营收复合增速更高（10.5% vs -2.6%）
礼蓝动物保健是一家美国动物保健制药企业，专注于生产宠物及家畜用药品与疫苗。该公司原为礼来公司旗下子公司，2019年完成分拆独立，目前是全球第三大动物保健企业。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
ELAN vs ROP — 直观对比
营收规模更大
ROP
是对方的1.8倍
$1.1B
营收增速更快
ELAN
高出0.9%
11.3%
净利率更高
ROP
高出39.9%
-24.1%
自由现金流更多
ROP
多$461.0M
$46.0M
两年增速更快
ROP
近两年复合增速
-2.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $2.1B |
| 净利润 | $-276.0M | $331.0M |
| 毛利率 | 51.5% | 69.4% |
| 营业利润率 | -22.6% | 27.2% |
| 净利率 | -24.1% | 15.8% |
| 营收同比 | 12.2% | 11.3% |
| 净利润同比 | -3350.0% | 53.7% |
| 每股收益（稀释后） | $-0.55 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELANROP
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.1B | $2.0B | ||
| Q2 25 | $1.2B | $1.9B | ||
| Q1 25 | $1.2B | $1.9B | ||
| Q4 24 | $1.0B | $1.9B | ||
| Q3 24 | $1.0B | $1.8B | ||
| Q2 24 | $1.2B | $1.7B |
净利润ELANROP
| Q1 26 | — | $331.0M | ||
| Q4 25 | $-276.0M | $428.4M | ||
| Q3 25 | $-34.0M | $398.5M | ||
| Q2 25 | $11.0M | $378.3M | ||
| Q1 25 | $67.0M | $331.1M | ||
| Q4 24 | $-8.0M | $462.3M | ||
| Q3 24 | $364.0M | $367.9M | ||
| Q2 24 | $-50.0M | $337.1M |
毛利率ELANROP
| Q1 26 | — | 69.4% | ||
| Q4 25 | 51.5% | 69.5% | ||
| Q3 25 | 53.4% | 69.5% | ||
| Q2 25 | 57.5% | 69.2% | ||
| Q1 25 | 57.3% | 68.7% | ||
| Q4 24 | 50.9% | 68.3% | ||
| Q3 24 | 52.2% | 69.2% | ||
| Q2 24 | 58.2% | 69.5% |
营业利润率ELANROP
| Q1 26 | — | 27.2% | ||
| Q4 25 | -22.6% | 28.6% | ||
| Q3 25 | -4.4% | 28.4% | ||
| Q2 25 | 2.0% | 28.2% | ||
| Q1 25 | 5.0% | 27.9% | ||
| Q4 24 | -5.0% | 28.0% | ||
| Q3 24 | 54.3% | 28.1% | ||
| Q2 24 | -2.7% | 28.8% |
净利率ELANROP
| Q1 26 | — | 15.8% | ||
| Q4 25 | -24.1% | 20.8% | ||
| Q3 25 | -3.0% | 19.8% | ||
| Q2 25 | 0.9% | 19.5% | ||
| Q1 25 | 5.6% | 17.6% | ||
| Q4 24 | -0.8% | 24.6% | ||
| Q3 24 | 35.3% | 20.8% | ||
| Q2 24 | -4.2% | 19.6% |
每股收益（稀释后）ELANROP
| Q1 26 | — | $4.87 | ||
| Q4 25 | $-0.55 | $3.97 | ||
| Q3 25 | $-0.07 | $3.68 | ||
| Q2 25 | $0.02 | $3.49 | ||
| Q1 25 | $0.13 | $3.06 | ||
| Q4 24 | $-0.01 | $4.29 | ||
| Q3 24 | $0.73 | $3.40 | ||
| Q2 24 | $-0.10 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $545.0M | $382.9M |
| 总债务越低越好 | $3.9B | $9.7B |
| 股东权益账面价值 | $6.5B | $18.8B |
| 总资产 | $13.4B | $34.6B |
| 负债/权益比越低杠杆越低 | 0.60× | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资ELANROP
| Q1 26 | — | $382.9M | ||
| Q4 25 | $545.0M | $297.4M | ||
| Q3 25 | $505.0M | $320.0M | ||
| Q2 25 | $539.0M | $242.4M | ||
| Q1 25 | $487.0M | $372.8M | ||
| Q4 24 | $468.0M | $188.2M | ||
| Q3 24 | $490.0M | $269.6M | ||
| Q2 24 | $416.0M | $251.5M |
总债务ELANROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | $3.9B | $9.3B | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | $7.6B | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — |
股东权益ELANROP
| Q1 26 | — | $18.8B | ||
| Q4 25 | $6.5B | $19.9B | ||
| Q3 25 | $6.7B | $20.0B | ||
| Q2 25 | $6.8B | $19.6B | ||
| Q1 25 | $6.4B | $19.2B | ||
| Q4 24 | $6.1B | $18.9B | ||
| Q3 24 | $6.5B | $18.5B | ||
| Q2 24 | $5.9B | $18.1B |
总资产ELANROP
| Q1 26 | — | $34.6B | ||
| Q4 25 | $13.4B | $34.6B | ||
| Q3 25 | $13.6B | $34.6B | ||
| Q2 25 | $13.7B | $33.2B | ||
| Q1 25 | $12.9B | $31.4B | ||
| Q4 24 | $12.6B | $31.3B | ||
| Q3 24 | $13.3B | $31.6B | ||
| Q2 24 | $13.8B | $29.8B |
负债/权益比ELANROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | 0.60× | 0.47× | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | 0.40× | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $108.0M | — |
| 自由现金流经营现金流 - 资本支出 | $46.0M | $507.0M |
| 自由现金流率自由现金流/营收 | 4.0% | 24.2% |
| 资本支出强度资本支出/营收 | 5.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $284.0M | — |
8季度趋势，按日历期对齐
经营现金流ELANROP
| Q1 26 | — | — | ||
| Q4 25 | $108.0M | $738.0M | ||
| Q3 25 | $219.0M | $869.5M | ||
| Q2 25 | $237.0M | $404.1M | ||
| Q1 25 | $-4.0M | $528.7M | ||
| Q4 24 | $177.0M | $722.2M | ||
| Q3 24 | $162.0M | $755.4M | ||
| Q2 24 | $200.0M | $384.1M |
自由现金流ELANROP
| Q1 26 | — | $507.0M | ||
| Q4 25 | $46.0M | — | ||
| Q3 25 | $127.0M | — | ||
| Q2 25 | $180.0M | — | ||
| Q1 25 | $-69.0M | — | ||
| Q4 24 | $130.0M | — | ||
| Q3 24 | $120.0M | — | ||
| Q2 24 | $166.0M | — |
自由现金流率ELANROP
| Q1 26 | — | 24.2% | ||
| Q4 25 | 4.0% | — | ||
| Q3 25 | 11.2% | — | ||
| Q2 25 | 14.5% | — | ||
| Q1 25 | -5.8% | — | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 14.0% | — |
资本支出强度ELANROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 5.4% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 4.6% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 4.6% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | 2.9% | — |
现金转化率ELANROP
| Q1 26 | — | — | ||
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 2.18× | ||
| Q2 25 | 21.55× | 1.07× | ||
| Q1 25 | -0.06× | 1.60× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 0.45× | 2.05× | ||
| Q2 24 | — | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
ROP
暂无分部数据
